Full Text:   <1999>

Summary:  <1525>

CLC number: R589

On-line Access: 2016-11-03

Received: 2016-01-08

Revision Accepted: 2016-03-25

Crosschecked: 2016-10-18

Cited: 0

Clicked: 3309

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2016 Vol.17 No.11 P.842-849

http://doi.org/10.1631/jzus.B1600009


Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia


Author(s):  Radosław Wieczór, Anna Maria Wieczór, Grażyna Gadomska, Katarzyna Stankowska, Jacek Fabisiak, Karol Suppan, Grzegorz Pulkowski, Jacek Budzyński, Danuta Rość

Affiliation(s):  Department of Pathophysiology, Faculty of Pharmacy, Nicolaus Copernicus University in Toruń, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Bydgoszcz PL 85-094, Poland; more

Corresponding email(s):   wieczorcmumk@tlen.pl

Key Words:  Overweight, Obesity, Angiogenesis, Vascular endothelial growth factor, Soluble type-1 and type-2 receptors, Peripheral arterial disease


Radosław Wieczór, Anna Maria Wieczór, Grażyna Gadomska, Katarzyna Stankowska, Jacek Fabisiak, Karol Suppan, Grzegorz Pulkowski, Jacek Budzyński, Danuta Rość. Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia[J]. Journal of Zhejiang University Science B, 2016, 17(11): 842-849.

@article{title="Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia",
author="Radosław Wieczór, Anna Maria Wieczór, Grażyna Gadomska, Katarzyna Stankowska, Jacek Fabisiak, Karol Suppan, Grzegorz Pulkowski, Jacek Budzyński, Danuta Rość",
journal="Journal of Zhejiang University Science B",
volume="17",
number="11",
pages="842-849",
year="2016",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1600009"
}

%0 Journal Article
%T Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia
%A Radosław Wieczór
%A Anna Maria Wieczór
%A Grażyna Gadomska
%A Katarzyna Stankowska
%A Jacek Fabisiak
%A Karol Suppan
%A Grzegorz Pulkowski
%A Jacek Budzyński
%A Danuta Rość
%J Journal of Zhejiang University SCIENCE B
%V 17
%N 11
%P 842-849
%@ 1673-1581
%D 2016
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1600009

TY - JOUR
T1 - Overweight and obesity versus concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 in plasma of patients with lower limb chronic ischemia
A1 - Radosław Wieczór
A1 - Anna Maria Wieczór
A1 - Grażyna Gadomska
A1 - Katarzyna Stankowska
A1 - Jacek Fabisiak
A1 - Karol Suppan
A1 - Grzegorz Pulkowski
A1 - Jacek Budzyński
A1 - Danuta Rość
J0 - Journal of Zhejiang University Science B
VL - 17
IS - 11
SP - 842
EP - 849
%@ 1673-1581
Y1 - 2016
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1600009


Abstract: 
Objective: Being overweight or obese comprises a significant risk factor for atherosclerosis. Fat tissue also generates factors stimulating angiogenesis, the process by which new blood vessels form. The purpose of this paper is to assess concentrations of the vascular endothelial growth factor A (VEGF-A) and its soluble type-1 and type-2 receptors (sVEGFR-1 and sVEGFR-2) in plasma of patients with peripheral arterial disease (PAD) depending on the level of nutrition according to body mass index (BMI). Methods: The study group included patients suffering from symptomatic PAD (n=46) in Fontaine classes IIa–IV without any history of neoplastic disease and who have a normal BMI (n=15), are overweight (n=21) or are obese (n=10). The control group (n=30) consisted of healthy non-smoking volunteers who were neither overweight nor obese. Venous blood plasma samples were collected from both groups at rest in the morning to determine plasma concentrations of VEGF-A, sVEGFR-1, and sVEGFR-2 using the enzyme-linked immunosorbent assay (ELISA) method. Results: The group of patients with PAD co-existent with being overweight or obese tended to have higher mean concentration levels of VEGF-A and sVEGFR-2 when compared with patients suffering from PAD with normal BMI. A statistically significant positive correlation was obtained between BMI and average plasma concentrations of sVEGFR-2 (R=0.37, P=0.0103). However, no significant correlation was noticed between BMI and VEGF-A or sVEGFR-1 concentrations. Conclusions: A positive correlation determined between the level of antiangiogenic factor and BMI value may be indicative of the linearly growing prevalence of some antiangiogenic factors in patients with metabolic disorders, which may be one of numerous factors contributing to incomplete efficiency of collateral circulation development in patients with PAD.

下肢慢性缺血患者的超重和肥胖对血浆中VEGF-A、VEGFR-1和VEGFR-2浓度的影响

目的:研究外周动脉疾病(PAD)患者血浆中血管内皮生长因子A(VEGF-A)和它的可溶性1型和2型受体(sVEGFR-1和sVEGFR-2)的浓度与营养水平的关系,同时根据身体质量指数(BMI)来评估营养水平。
创新点:将血管生成与超重和肥胖及下肢局部缺血联系起来,并根据BMI评估了它们之间的关系。
方法:研究组包括46名Fontaine等级IIa至IV且没有任何肿瘤疾病史的PAD症状患者,其中15名BMI正常,21名超重,10名肥胖。对照组由30名不超重且不肥胖的健康非吸烟志愿者组成。试验在上午休息时间采集两组静脉血的血浆标本,用酶联免疫吸附(ELISA)方法确定血浆中的VEGF-A、sVEGFR-1和sVEGFR-2浓度。
结论:如果PAD患者同时伴随着超重或者肥胖,会影响血管再生的过程。sVEGFR-2水平和BMI值之间有正相关关系,这说明代谢紊乱患者中的一些抗血管生成因子患病率的线性增长的原因,同时这可能是导致PAD患者侧支循环发展效率不完全的众多因素之一。

关键词:超重;肥胖;血管生成;血管内皮生长因子;可溶性1型和2型受体;外周动脉疾病

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Ahmadvand, D., Rahbarizadeh, F., Iri-Sofla, F.J., et al., 2010. Inhibition of angiogenesis by recombinant VEGF receptor fragments. Lab. Med., 41(7):417-422.

[2]Barańska, P., Jerczyńska, H., Pawłowska, Z., 2005. Vascular endothelial growth factor-structure and functions. Postepy Biochem., 51(1):12-21 (in Polish).

[3]Biela, U., Pająk, A., Kaczmarczyk-Chałas, K., et al., 2005. Incidence of overweight and obesity in women and men between the ages of 20–74. Results of the WOBASZ program. Kardiol. Pol., 63(6 Suppl. 4):s632-s635 (in Polish).

[4]Bouloumié, A., Drexler, H., Lafontan, M., et al., 1998. Leptin, the product of Ob gene, promotes angiogenesis. Circ. Res., 83(10):1059-1066.

[5]Findley, C.M., Mitchell, R.G., Duscha, B.D., et al., 2008. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. J. Am. Coll. Cardiol., 52(5):387-393.

[6]Isner, J.M., Pieczek, A., Shainfeld, R., et al., 1996. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet, 348(9024):370-374.

[7]Kajdaniuk, D., Marek, B., Fołtyn, W., et al., 2011. Vascular endothelial growth factor (VEGF) in endocrinology and oncology. Endokrynol. Pol., 62(Suppl. 3):14-22 (in Polish).

[8]Kou, B., Li, Y., Zhang, L., et al., 2004. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Exp. Mol. Pathol., 76(2):129-137.

[9]Lijnen, H.R., 2008. Angiogenesis and obesity. Cardiovasc. Res., 78(2):286-293.

[10]Liu, W., Zhang, X., Song, C., et al., 2014. Expression and characterization of a soluble VEGF receptor 2 protein. Cell Biosci., 4(1):14.

[11]Loebig, M., Klement, J., Schmoller, A., et al., 2010. Evidence for relationship between VEGF and BMI independent of insulin sensitivity by glucose clamp procedure in a homogenous group healthy young men. PLOS ONE, 5(9):e12610.

[12]Miyazawa-Hoshimoto, S., Takahashi, K., Bujo, H., et al., 2003. Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia, 46(11):1483-1488. http://dx.doi.org/10.1007/s00125-003-1221-6

[13]Mizia-Malarz, A., Sobol, G., Woś, H., 2008. Angiogenesis in the chronic inflammatory diseases and malignancies. Pol. Merkur. Lekarski, 24(141):185-189 (in Polish).

[14]Proczka, R., Polański, J., Małecki, M., et al., 2003. The significance of vascular endothelial growth factor in the neoangiogenesis process. The role of hypoxia in the endothelial cells proliferation process and in the formation of collateral circulation. Acta Angiol., 9(4):143-149 (in Polish).

[15]Rehman, J., Considine, R.V., Bovenkerk, J.E., et al., 2003. Obesity is associated with increased levels of circulating hepatocyte growth factor. J. Am. Coll. Cardiol., 41(8):1408-1413.

[16]Rość, D., Wieczór, R., Stankowska, K., et al., 2014. Plasma VEGF-A/SVEGFR-1 ratio as a potential ischemic marker in patients with symptomatic peripheral arterial disease– preliminary report. Thromb Res., 133(Suppl. 3):S95.

[17]Sandhofer, A., Tatarczyk, T., Kirchmair, R., et al., 2009. Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study. Atherosclerosis, 206(1):265-269.

[18]Silha, J.V., Krsek, M., Sucharda, P., et al., 2005. Angiogenic factors are elevated in overweight and obese individuals. Int. J. Obesity (Lond.), 29(11):1308-1314.

[19]Skóra, J., Barć, P., Pupka, A., et al., 2013. Transplantation of autologous bone marrow mononuclear cells with VEGF gene improves diabetic critical limb ischaemia. Endokrynol. Pol., 64(2):129-138.

[20]Stehr, A., Töpel, I., Müller, S., et al., 2010. VEGF: a surrogate marker for peripheral vascular disease. Eur. J. Vasc. Endovasc., 39(3):330-332.

[21]Świątkowska-Stodulska, R., Kazimierska, E., Sworczak, K., et al., 2007. Hemostatic disturbances in obesity. Wiad. Lek., 60(3-4):185-188 (in Polish).

[22]Tendera, M., Aboyans, V., Bartrelink, M.L., et al., 2011. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The task force on the diagnosis and treatment of peripheral artery diseases of the European Society of Cardiology (ESC). Eur. Heart J., 32(22):2851-2906.

[23]Wada, H., Ura, S., Kitaoka, S., et al., 2011. Distinct characteristics of circulating vascular endothelial growth factor-A and C levels in human subjects. PLOS ONE, 6(12):e29351.

[24]Wieczór, R., Gadomska, G., Ruszkowska-Ciastek, B., et al., 2015a. Impact of type 2 diabetes on the plasma levels of vascular endothelial growth factor and its soluble receptors type 1 and type 2 in patients with peripheral arterial disease. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 16(11):948-956.

[25]Wieczór, R., Gadomska, G., Góralczyk, B., et al., 2015b. Selected angiogenic factors in plasma of patients with lower limb symptomatic peripheral arterial disease— preliminary report. Int. Angiol., 34(6):545-551.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE